Elias Castaneda
|
 |
The reports follow a well-publicized Harvard Medical School study that found consumer ads had little effect on prescription drug sales. It launched drug store pharmacist tramadol a "Be Smart about Prescription Drug Advertising" area online at. "The pharmaceutical companies perceive the threat of government regulation on marketing sleeping pills to be a stronger threat now than it has been in the past," and are trying to self-regulate, Swallen says. Among factors driving the drop, he says, are fewer drug launches, fear of government regulation and cuts by a few brands that had spent big. Sepracor's Lunesta, sleeping pills an insomnia drug known for its glowing moth icon, spent $75million on ads in the first quarter of 2008 vs. A service of YellowBrix, Inc.. Some field officer brands, such as Pfizer's Lipitor, have revamped ads under rozerem government pressure. Researchers focused on ads for three drugs. Those declines are an abrupt reversal from the robust spending growth of a few years ago. Rival ad tracker Nielsen Monitor-Plus calculates the tip at 4.8% to $2.7 billion. And it rozerem comes as they already are dealing with large spending declines in some other major ad categories, such as automotive and telecommunications, and recession fears, thanks to the online pharmacy crisis on Wall Street. That if the government gets involved, they'll be worse off." Last month, the Food and Drug Administration stepped up its watch by asking consumers to help watch for false or misleading drug ads. The site encourages consumers to keep rozerem drug an eye out for false or misleading ads and provides a caldwell to report violators. By Addi Petrecca NEW YORK -- This could make media owners sick. TNS Media Intelligence puts the drop at 3.9% to $2.4 billion. (c) 2008 USA Just now, a division of Gannett Co. Pharmaceutical ad spending they count on to exceed $5 billion a year is losing its potency. Magazines and radio stations have seen the most drug ad decline. $175million in that quarter in 2007. Second-quarter spending in magazines fell 29% to $358million, according to TNS, while radio plummeted 62% to $4million. Enbrel (for rheumatoid arthritis), Nasonex (nasal allergies) and Zelnorm (irritable bowel syndrome). "Throughout much of the early decade, it was growing at strong double-digit rates as pharmaceutical marketers become more comfortable and experienced with DTC advertising," says Jon Swallen, TNS senior vice president of research. Takeda Pharmaceuticals North America's Rozerem sleep aid, which used offbeat ad characters such as Ellsworth Talbert and a beaver, cut spending from $91million in the first half of 2007 to $15million in the first half this year. Two recent reports say drugmakers cut Rx ad spending in the first six months of this year. Results sho that direct-to-consumer (DTC) ads "probably aren't as effective as widely perceived," says Zebulon Law, lead That bodes ill for the magazines, newspapers and radio and TV outlets for which the ads have been a prescription for profits.
|